Compare Gilead Sciences, Inc. (GILD) vs J B Hunt Transport Services Inc (JBHT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs J B Hunt Transport Services Inc — how do they compare? Gilead Sciences, Inc. trades at $135.26 (market cap $164.99B), while J B Hunt Transport Services Inc trades at $265.38 (market cap $24.98B). The key difference: Gilead Sciences, Inc. is far larger — about 6.6× J B Hunt Transport Services Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.47%). Which is the better fit depends on your goals.
| GILD | JBHT | |
|---|---|---|
Market Cap | $164.99B | $24.98B |
Sector | Health | Industrials |
52-Week High | $155.80 | $298.41 |
52-Week Low | $110.56 | $130.65 |
Enterprise Value | $188.06B | $26.12B |
Dividend Yield | 2.47% | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JBHT trades at $268.52, up 0.48% today, with a bearish technical signal but strong fundamentals. The stock shows consistent earnings beats, with Q2 2026 EPS of $1.91 exceeding the $1.74 estimate. Revenue trends have stabilized around $12B annually, while net income margin improved to 5.31% in 2025. Analyst consensus is bullish with a $299.82 price target, supported by institutional buying and positive news on intermodal demand growth.
Outlook is positive due to earnings momentum and sector tailwinds, but risks include economic sensitivity and high P/E of 38.18. The stock offers growth potential with manageable volatility, appealing for investors seeking transportation exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →
